Rezolute, Inc. Common Stock (NV)
RZLTStock
$4.37−7.24%52W
Market Cap$420.80M
P/E—
Div yield—
Beta0.58
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)92.24%
Price vs S&P 500 (4W)3.12%
VGM Score61.96
Market Capitalization$420.80M
Earnings Surprise History
Q3 26-0.16est. -0.18
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.13
4.13
4.19
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RZLTRezolute, Inc. Common Stock (NV) | — | — | B | $4.37 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases, including congenital hyperinsulinism, a rare endocrine disorder characterized by excessive insulin production and hypoglycemia. Its pipeline candidates aim to improve patient outcomes with reduced treatment burdens. Value creation depends on successful clinical development and regulatory approval.